New insider activity at Irhythm Technologies ( (IRTC) ) has taken place on March 3, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Irhythm Technologies has seen a flurry of insider selling, with multiple top executives offloading significant stakes in the company. President & CEO Quentin Blackford led the activity by selling 13,813 shares for $1,774,141. CBO and CLO Patrick Michael Murphy sold 4,357 shares worth $559,592, while EVP & CRO Sumi Shrishrimal disposed of 2,830 shares for $363,466. CFO Daniel G. Wilson sold 3,395 shares valued at $436,064, and Chief Communications & Product Officer Chad Patterson sold 4,444 shares for $570,787. Chief Medical/Science Officer and EVP of Advanced Technology Minang Turakhia sold 4,027 shares for $517,240. Additionally, CAO Marc W. Rosenbaum sold 816 shares for $104,811, and EVP of Strategic Business Operations Mervin Smith sold 1,352 shares totaling $173,643. Together, these transactions highlight substantial recent stock sales across Irhythm’s senior leadership team.
Recent Updates on IRTC stock
IRhythm shares fell about 6% after the company disclosed a civil investigative demand from the U.S. DOJ tied to Zio AT reimbursement, extending an existing 2023 subpoena and adding legal and reimbursement overhang to the story. Despite this, the firm’s Q4 call highlighted strong volume‑driven revenue growth, margin expansion, first‑time quarterly profitability and conservative 2026 guidance.
Multiple banks trimmed their price targets as they recalibrated valuation multiples and risk assumptions in light of sector‑wide multiple compression, the DOJ inquiry and regulatory/MCT‑launch timing uncertainties, even as core fundamentals and Zio AT momentum remained solid. Analysts cited the combination of legal scrutiny, reimbursement complexity and moderated growth outlook as reasons to temper expectations while still acknowledging iRhythm’s leading market position and improving cash flow profile.
Spark’s Take on IRTC Stock
According to Spark, TipRanks’ AI Analyst, IRTC is a Neutral.
The score is driven primarily by improving fundamentals and a positive outlook from the latest earnings call (growth, margin expansion, and rising free cash flow). Offsetting this are elevated balance-sheet leverage, still-negative profitability/negative P/E, and weak technicals with the stock trading below key moving averages.
To see Spark’s full report on IRTC stock, click here.
More about Irhythm Technologies
YTD Price Performance: -27.60%
Average Trading Volume: 634,977
Technical Sentiment Signal: Hold
Current Market Cap: $4.15B